These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 30197228)

  • 21. FDA Approves Nalmefene, a Longer-Lasting Opioid Reversal Nasal Spray.
    Harris E
    JAMA; 2023 Jun; 329(23):2012. PubMed ID: 37256577
    [No Abstract]   [Full Text] [Related]  

  • 22. Discrimination of a single dose of morphine followed by naltrexone: substitution of other agonists for morphine and other antagonists for naltrexone in a rat model of acute dependence.
    Holtzman SG
    J Pharmacol Exp Ther; 2003 Mar; 304(3):1033-41. PubMed ID: 12604679
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A double-blind, placebo-controlled study of oral nalmefene for alcohol dependence.
    Mason BJ; Salvato FR; Williams LD; Ritvo EC; Cutler RB
    Arch Gen Psychiatry; 1999 Aug; 56(8):719-24. PubMed ID: 10435606
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Low-dose naltrexone and opioid consumption: a drug utilization cohort study based on data from the Norwegian prescription database.
    Raknes G; Småbrekke L
    Pharmacoepidemiol Drug Saf; 2017 Jun; 26(6):685-693. PubMed ID: 28370746
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Population pharmacokinetics of nalmefene in healthy subjects and its relation to μ-opioid receptor occupancy.
    Kyhl LE; Li S; Faerch KU; Soegaard B; Larsen F; Areberg J
    Br J Clin Pharmacol; 2016 Feb; 81(2):290-300. PubMed ID: 26483076
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of liver disease on the disposition of the opioid antagonist nalmefene.
    Frye RF; Matzke GR; Schade R; Dixon R; Rabinovitz M
    Clin Pharmacol Ther; 1997 Jan; 61(1):15-23. PubMed ID: 9024170
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prolonged blockade of opioid effect with oral nalmefene.
    Gal TJ; DiFazio CA; Dixon R
    Clin Pharmacol Ther; 1986 Nov; 40(5):537-42. PubMed ID: 3533370
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effectiveness and safety of intravenous nalmefene for emergency department patients with suspected narcotic overdose: a pilot study.
    Kaplan JL; Marx JA
    Ann Emerg Med; 1993 Feb; 22(2):187-90. PubMed ID: 8427429
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Withdrawal syndrome after co-medication of opioid maintenance therapy with nalmefene: unrecognized interaction.
    Diot C; Eiden C; Roussin A; Batisse A; Boucher A; Chavant F; Daveluy A; Donadieu-Rigole H; Peyrière H;
    Eur J Clin Pharmacol; 2015 Dec; 71(12):1539-40. PubMed ID: 26329380
    [No Abstract]   [Full Text] [Related]  

  • 30. Comparing Nalmefene and Naltrexone in Alcohol Dependence: Are there any Differences? Results from an Indirect Meta-Analysis.
    Soyka M; Friede M; Schnitker J
    Pharmacopsychiatry; 2016 Mar; 49(2):66-75. PubMed ID: 26845589
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Continuous delivery of naltrexone and nalmefene leads to tolerance in reducing alcohol drinking and to supersensitivity of brain opioid receptors.
    Korpi ER; Linden AM; Hytönen HR; Paasikoski N; Vashchinkina E; Dudek M; Herr DR; Hyytiä P
    Addict Biol; 2017 Jul; 22(4):1022-1035. PubMed ID: 26990998
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prolonged central mu-opioid receptor occupancy after single and repeated nalmefene dosing.
    Ingman K; Hagelberg N; Aalto S; Någren K; Juhakoski A; Karhuvaara S; Kallio A; Oikonen V; Hietala J; Scheinin H
    Neuropsychopharmacology; 2005 Dec; 30(12):2245-53. PubMed ID: 15956985
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nalmefene for elective reversal of procedural sedation in children.
    Chumpa A; Kaplan RL; Burns MM; Shannon MW
    Am J Emerg Med; 2001 Nov; 19(7):545-8. PubMed ID: 11698998
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Opioid Receptor Antagonists in the Treatment of Alcoholism.
    Serecigni JG
    Adicciones; 2015 Sep; 27(3):214-30. PubMed ID: 26437315
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nalmefene for the treatment of alcohol use disorders: recent data and clinical potential.
    Soyka M
    Expert Opin Pharmacother; 2016; 17(4):619-26. PubMed ID: 26810044
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nalmefene: a long-acting opioid antagonist. Clinical applications in emergency medicine.
    Wang DS; Sternbach G; Varon J
    J Emerg Med; 1998; 16(3):471-5. PubMed ID: 9610980
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeted nalmefene with simple medical management in the treatment of heavy drinkers: a randomized double-blind placebo-controlled multicenter study.
    Karhuvaara S; Simojoki K; Virta A; Rosberg M; Löyttyniemi E; Nurminen T; Kallio A; Mäkelä R
    Alcohol Clin Exp Res; 2007 Jul; 31(7):1179-87. PubMed ID: 17451401
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Acute effects of nalmefene on LH, prolactin, and testosterone in male rhesus monkeys.
    Mello NK; Mendelson JH; Kelly M
    Pharmacol Biochem Behav; 2000 Jun; 66(2):275-83. PubMed ID: 10880679
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A review of the potential role of methylnaltrexone in opioid bowel dysfunction.
    Foss JF
    Am J Surg; 2001 Nov; 182(5A Suppl):19S-26S. PubMed ID: 11755893
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical experience about an unexpected adverse event during nalmefene treatment in two patients with alcohol use disorder.
    Milano G; Zavan V; Natta WM; Martelli A; Mattioli F
    J Clin Pharm Ther; 2016 Feb; 41(1):97-100. PubMed ID: 26714742
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.